Literature DB >> 12079851

The sphingomyelin-signaling pathway in skeletal muscles and its role in regulation of glucose uptake.

Jan Górski1, Agnieszka Dobrzyn, Malgorzata Zendzian-Piotrowska.   

Abstract

Sphingomyelin has been shown to be a source of bioactive compounds. This sphingolipid is located mostly in the outer layer of the plasma membrane and in the membranes of organelles. Sphingomyelin located in the plasma membrane is hydrolyzed into ceramide and phosphorylcholine. Ceramide is the principal second messenger in the sphingomyelin transmembrane signaling pathway. Products of ceramide metabolism, namely, sphingosine, sphingosine-1-phosphate, and ceramide-1-phosphate, also exert broad biological effects. The major effects of ceramide are induction of differentiation, inhibition of proliferation, regulation of inflammatory processes, and induction of apoptosis. There is also convincing evidence that ceramide counteracts insulin-stimulated glucose uptake. Ceramides are also present in skeletal muscles. We investigated ceramide metabolism in different skeletal muscle types of the rat at rest and after prolonged exercise of moderate intensity. Exercise reduced the total content of ceramide fatty acids and changed their composition in each muscle type. These data indicate that the sphingomyelin-signaling pathway functions in skeletal muscles and that its activity is downregulated during prolonged exercise. The content of ceramide in the muscles was inversely related to 2-deoxyglucose uptake by the muscles. This indicates that ceramide may be involved in regulation of glucose uptake by skeletal muscles in vivo.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12079851     DOI: 10.1111/j.1749-6632.2002.tb04279.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  10 in total

Review 1.  Sphingolipid metabolism, oxidant signaling, and contractile function of skeletal muscle.

Authors:  Mariana N Nikolova-Karakashian; Michael B Reid
Journal:  Antioxid Redox Signal       Date:  2011-06-08       Impact factor: 8.401

2.  Human skeletal muscle ceramide content is not a major factor in muscle insulin sensitivity.

Authors:  M Skovbro; M Baranowski; C Skov-Jensen; A Flint; F Dela; J Gorski; J W Helge
Journal:  Diabetologia       Date:  2008-05-06       Impact factor: 10.122

Review 3.  Sphingolipids, insulin resistance, and metabolic disease: new insights from in vivo manipulation of sphingolipid metabolism.

Authors:  William L Holland; Scott A Summers
Journal:  Endocr Rev       Date:  2008-05-01       Impact factor: 19.871

4.  Genetic analysis of hyl-1, the C. elegans homolog of LAG1/LASS1.

Authors:  Patricia Tedesco; James Jiang; Jinqing Wang; S Michal Jazwinski; Thomas E Johnson
Journal:  Age (Dordr)       Date:  2008-02-16

5.  The role of skeletal muscle sphingolipids in the development of insulin resistance.

Authors:  Marek Straczkowski; Irina Kowalska
Journal:  Rev Diabet Stud       Date:  2008-05-10

Review 6.  Sphingolipids in obesity, type 2 diabetes, and metabolic disease.

Authors:  S B Russo; J S Ross; L A Cowart
Journal:  Handb Exp Pharmacol       Date:  2013

7.  Sphingolipid regulators of cellular dysfunction in Type 2 diabetes mellitus: a systems overview.

Authors:  Jessica S Ross; Sarah B Russo; Georgia C Chavis; Lauren A Cowart
Journal:  Clin Lipidol       Date:  2017-01-18

8.  Sphingolipid content of human adipose tissue: relationship to adiponectin and insulin resistance.

Authors:  Agnieszka U Blachnio-Zabielska; Christina Koutsari; Tamara Tchkonia; Michael D Jensen
Journal:  Obesity (Silver Spring)       Date:  2012-05-07       Impact factor: 5.002

9.  Effects of endurance exercise and high-fat diet on insulin resistance and ceramide contents of skeletal muscle in sprague-dawley rats.

Authors:  Hyun Lyung Jung; Ho Youl Kang
Journal:  Korean Diabetes J       Date:  2010-08-31

10.  Fiber specific changes in sphingolipid metabolism in skeletal muscles of hyperthyroid rats.

Authors:  A Chabowski; M Zendzian-Piotrowska; A Mikłosz; B Łukaszuk; K Kurek; J Górski
Journal:  Lipids       Date:  2013-03-07       Impact factor: 1.880

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.